# A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Source: https://onco.cc/trials/nct07128199/  
OnCo record `nct07128199` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Zipalertinib in non-small-cell lung cancer, active and no longer recruiting.

## Summary

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumour Resection is a phase 3 interventional study registered as NCT07128199, led by Taiho Oncology, and active but no longer recruiting on the registry. Official title: A Randomised, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumour Resection (REZILIENT4). Planned enrolment is 360 participants (estimated). The study started in 2025-12-22 and primary completion is expected in 2029-10-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: REZILIENT4
- Tags: ctgov-ingest
- Registry id: NCT07128199
- Phase: 3
- Setting: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
- Sponsor: Taiho Oncology
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT07128199: https://clinicaltrials.gov/study/NCT07128199

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- drugs: [Zipalertinib](https://onco.cc/drugs/zipalertinib/)
- companies: [Taiho Oncology (Otsuka)](https://onco.cc/companies/taiho-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct07128199.json